Clinical Trial

A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)

Name: A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study) — clinical trial record (NCT07499544)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-16

Trial Details

NCT Number	NCT07499544
Lead Sponsor	Huahui Health
Conditions	Chronic Hepatitis D Infection
Enrollment	160 participants
Start Date	2026-04-22
Primary Completion	2028-09-12 (estimated)
Study Completion	2030-01-29 (estimated)
Updated on ClinicalTrials.gov	2026-06-10